Omeros Corporation (NASDAQ:OMER) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six research firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

A number of equities analysts have recently weighed in on OMER shares. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research note on Friday, May 16th. HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Omeros in a research note on Friday, June 27th. D. Boral Capital restated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research note on Monday, June 30th. Finally, Wall Street Zen downgraded Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 27th.

Hedge Funds Weigh In On Omeros

Several institutional investors have recently bought and sold shares of OMER. Truvestments Capital LLC lifted its stake in Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP purchased a new position in Omeros in the fourth quarter valued at approximately $46,000. Picton Mahoney Asset Management lifted its stake in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 4,404 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Omeros by 14,486.3% in the first quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 7,388 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Stock Performance

OMER stock opened at $3.46 on Friday. The company has a market capitalization of $202.72 million, a P/E ratio of -1.31 and a beta of 2.16. Omeros has a 52-week low of $2.95 and a 52-week high of $13.60. The business has a 50-day simple moving average of $3.73 and a two-hundred day simple moving average of $6.83.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). As a group, sell-side analysts forecast that Omeros will post -3.09 earnings per share for the current fiscal year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.